-
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
•
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024, showing a 1.7% increase in global net sales to €5.4 billion (USD 5.9 billion) over the three-month period. The company’s performance varied by business segment, with Life Science experiencing a decline of 3.7% year-on-year in…
-
CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology
•
CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with the German pharmaceutical and chemical giant Merck KGaA (FRA: MRK). The agreement pertains to CybernaX’s proprietary technology for efficient lipid storage. While the financial details of the transaction remain undisclosed, the partnership signals a significant…
